Co-Authors
This is a "connection" page, showing publications co-authored by ANTHONY PAUL CONLEY and BEHRANG AMINI.
Connection Strength
0.888
-
Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother. 2022 10 01; 45(8):374-378.
Score: 0.219
-
Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. Curr Oncol Rep. 2018 03 26; 20(5):37.
Score: 0.162
-
MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours. Br J Radiol. 2016; 89(1058):20150308.
Score: 0.137
-
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter? Cancers (Basel). 2024 Feb 23; 16(5).
Score: 0.061
-
Management of chordoma and chondrosarcoma with definitive dose-escalated single-fraction spine stereotactic radiosurgery. J Neurooncol. 2023 Sep; 164(2):377-386.
Score: 0.059
-
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023 02; 12(4):4282-4293.
Score: 0.055
-
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.
Score: 0.055
-
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer. 2022 09 15; 128(18):3383-3391.
Score: 0.054
-
Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor. Clin Sarcoma Res. 2020; 10:14.
Score: 0.048
-
Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep. 2017 08 25; 7(1):9519.
Score: 0.039